CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon
- Citation:
- Ann Oncol vol 25 (suppl 4) 5010
- Meeting Instance:
- ESMO 2014
- Year:
- 2014
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2637
- Pharmas:
- Grants:
- Corr. Author:
- H. Lenz
- Authors:
- H. Lenz D. Niedzwiecki F. Innocenti C. Blanke M. Mahoney B. O'Neil J. Shaw B. Polite H. Hochster J. Atkins R. Goldberg R. Mayer R. Schilsky M. Bertagnolli A. Venook
- Networks:
- Study
- Alliance-80405
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- Keywords: